Related Experiment Video

Updated: Jun 27, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway

Martin J Gunthorpe1, Boris A Chizh

  • 1Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, UK. Martin_J_Gunthorpe@gsk.com

Drug Discovery Today
|December 10, 2008
PubMed

Insights

Novel antagonists targeting the TRPV1 receptor show promise for pain relief. Early clinical trials indicate these TRPV1 antagonists have anti-hyperalgesic effects in humans, offering a new therapeutic avenue for chronic pain management.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Discovery

Background:

  • Transient Receptor Potential Vanilloid 1 (TRPV1) is a key receptor involved in pain signaling, activated by heat, capsaicin, and acid.
  • Developing antagonists for TRPV1 represents a novel therapeutic strategy for pain management.

Purpose of the Study:

  • To review recent advancements and challenges in the development of TRPV1 antagonists for pain treatment.
  • To assess the therapeutic potential of TRPV1 antagonists in managing chronic pain conditions.

Main Methods:

  • Review of current scientific literature on TRPV1 antagonist research.
  • Analysis of early clinical development data for TRPV1 antagonists.
  • Discussion of pharmacodynamic effects and anti-hyperalgesic actions observed in human studies.

Main Results:

  • TRPV1 antagonists have entered early clinical development.
  • Initial human studies demonstrate pharmacodynamic effects and anti-hyperalgesic activity consistent with TRPV1 antagonism.
  • These findings suggest potential for symptom relief in chronic pain patients.

Conclusions:

  • TRPV1 antagonists represent a promising new class of drugs for pain management.
  • Successful translation to chronic pain relief could provide a novel mechanism of action after many years.
  • The field of TRPV1 antagonist drug discovery is highly competitive and rapidly evolving.

More Related Videos

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 109:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Thermosensation01:43

Thermosensation

Peripheral thermosensation is the perception of external temperature. A change in temperature (on the surface of the skin and other tissues) is detected by a family of temperature-sensitive ion channels called Transient Receptor Potential, or TRP, receptors. These receptors are located on free nerve endings. Those detecting cold temperatures are closer to the surface of the skin than the nerve endings detecting warmth. These thermoTRP channels, while temperature selective, have relatively...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Nociception01:44

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.